阅读说明：本技术 用TTFields和Aurora激酶抑制剂治疗肿瘤 (Treatment of tumors with TTfields and Aurora kinase inhibitors ) 是由 莫舍·吉拉迪 戴玛·克雷斯 阿晴·谭米 罗莎·S·舒奈德曼 于 2019-04-08 设计创作，主要内容包括：可以通过将Aurora激酶抑制剂(例如MLN8237或另一种Aurora A激酶抑制剂、AZD1152或另一种Aurora B激酶抑制剂)施用于癌细胞,并且将频率为100至300 kHz(例如200 kHz)的交变电场施加于癌细胞,来降低癌细胞的生存力。此外,可以通过将Aurora激酶抑制剂施用于受试者,并且将频率为100至300 kHz(例如200 kHz)的交变电场施加于受试者的靶区域(例如,脑),来治疗受试者中的癌症(例如,成胶质细胞瘤)。(The viability of cancer cells can be reduced by applying an Aurora kinase inhibitor (e.g., MLN8237 or another Aurora a kinase inhibitor, AZD1152, or another Aurora B kinase inhibitor) to the cancer cells and applying an alternating electric field having a frequency of 100 to 300 kHz (e.g., 200 kHz) to the cancer cells. In addition, a cancer (e.g., glioblastoma) in a subject may be treated by administering an Aurora kinase inhibitor to the subject and applying an alternating electric field having a frequency of 100 to 300 kHz (e.g., 200 kHz) to a target region (e.g., brain) of the subject.)